跳至主要内容
临床试验/NL-OMON51144
NL-OMON51144已完成不适用

Management of psoriasis and risk and severity of COVID-19 infection in systemic, biologic and topical treatment for psoriasis during the COVID-19 pandemic: an epidemiological cohort study - PsoCovid

Bravis Ziekenhuis0 个研究点目标入组 1,500 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Subject is able to sign the informed consent form.
  • * Age of 18 years or older
  • * Subject is currently being treated for psoriasis with:
  • o Conventional systemic immunosuppressive therapy (CSIT) including:
  • methotrexate, cyclosporin A or fumaric acid. Concomitant topical therapy is
  • o Biological immunosuppressive therapy (BIT) including, but not limited to:
  • anti IL-17a, anti IL-23 or anti TNF-alpha biological agents. Concomitant
  • topical therapy is allowed. Combination with low dose MTX is allowed
  • o Topical therapy (TT) including corticosteroids, anthralin, calcipotriene,
  • topical vitamin D derivatives, retinoids, urea and medicated shampoos

排除标准

  • * Subject is being treated with immunosuppressive therapy for any indication
  • other than psoriasis
  • * Subject is incapacitated or otherwise incapable of participating in the

研究者

发起方
Bravis Ziekenhuis

相似试验